Jiangsu Hualan New Pharmaceutical Material Co (301093) Fair Value & Analysis
Healthcare · CN · Market cap 21.3B CNY
Fair value as of: Aug 13, 2026
From 13 valuation models · updated today
Share price −24.2% over the past month.
Below-average quality, and screening another 56% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥44.57). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
57‑month range ¥13.20 – ¥135.63 · fair‑value band ¥26.72 – ¥44.57 · the ¥81.50 price screens above the ¥35.65 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jiangsu Hualan New Pharmaceutical Material Co (301093) currently trades at ¥81.50, while our model-based Fair Value estimate is ¥35.65, implying the stock looks roughly 56.3% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Jiangsu Hualan New Pharmaceutical Material Co generated revenue of 603M CNY at a net margin of 7.0%. Revenue declined 11.0% year over year. It earns a return on equity of 1.9%. Net debt stands at 66.1M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥26.72 (bear case) to ¥44.57 (bull case); at ¥81.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 248% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -56%, 301093 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (¥8.95) versus Earnings-Based (¥4.74). Highest evidence: Residual Income (76).
Notify me when 301093 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the pharmaceuticals' industry in China and internationally.
Full company description
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the pharmaceuticals' industry in China and internationally. It offers covered rubber stoppers serise; halogenated butyl rubber stopper freeze-dryied series; halogenated butyl rubber stopper antibiotics series; halogenated butyl rubber plugs infusion series; combination cap series for plastic infusion vessels; polyisoprene gaskets; blood plugs; halogenated butyl rubber stopper for oral dosage forms; pre-potted protective caps; medical instruments; and pen style products. The company was founded in 1992 and is based in Jiangyin, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Hualan New Pharmaceutical Material Co reported revenue of ¥619M in FY2025 versus ¥821M in FY2021, a compound −6.8%/yr. Reported net income was ¥60.2M in FY2025, compounding −27.4%/yr from FY2021.
301093 screens 56% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 201 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Straumann Holding STMN | CHF 102.05 | CHF 47.31 | -54% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
Compare Jiangsu Hualan New Pharmaceutical Material Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangsu Hualan New Pharmaceutical Material Co (301093) overvalued or undervalued?
What is the fair value of 301093?
What is the quality score of 301093?
What is the revenue of Jiangsu Hualan New Pharmaceutical Material Co (301093)?
What is the net profit margin of 301093?
Does Jiangsu Hualan New Pharmaceutical Material Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangsu Hualan New Pharmaceutical Material Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.